SofWave Medical (SOFW) CG MedTech, Diagnostics and Digital Health & Services Forum summary

Key business highlights

• Achieved record Q3 revenue of $21.1 million, up 56% year-over-year, with a CAGR of 69% since 2020.

• 40% of revenue is recurring, driven by virtual consumable sales to physicians, not just capital equipment.

• Operating profit reached $1.9 million in Q3, with $26.5 million in cash and no debt.

• Over 50% of revenue comes from North America, with Asia-Pacific at 30%; recent regulatory approval in Japan and ongoing efforts in China.

• Net income for the first nine months was $1.4 million, with strong cash generation and profitability.

Technology and product innovation

• Patented ultrasound technology enables non-invasive skin tightening, lifting, and muscle toning with minimal downtime.

• Nine FDA clearances, including unique approvals for eyebrow lift and upper arm lifting.

• Recent launches include the Lift AG applicator for body treatments and a wireless EMS device for muscle toning.

• Devices are easy to delegate, safe, and offer fast treatments, supporting high clinic ROI.

• Continuous innovation with new applicators and features targeting emerging market needs, especially GLP-1 patient segment.

Market trends and strategy

• Aesthetic medical device market estimated at $4.1 billion, projected to grow at 13% CAGR.

• GLP-1 patient segment is driving new demand for skin tightening and muscle toning.

• 40% increase in demand for skin tightening procedures, while fat reduction treatments decline.

• Business model focuses on recurring revenue through virtual consumables, providing predictable ROI for clinics.

• Global expansion ongoing, with significant potential in China pending regulatory approval.